Epicutaneous Immunotherapy Effective for Toddlers With Peanut Allergy
Researchers evaluated the safety and efficacy of epicutaneous immunotherapy with a peanut protein patch in children 1 to 3 years of age with peanut allergy.
Researchers evaluated the safety and efficacy of epicutaneous immunotherapy with a peanut protein patch in children 1 to 3 years of age with peanut allergy.
Non-IgE-mediated food allergies are on the rise in children and do not always present with an immediate, anaphylaxis-type reaction
Food allergy and obesity raise COVID-19 infection risk, but asthma does not, according to an NIH-funded study.